Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 15:14:245-258.
doi: 10.2147/JAA.S296147. eCollection 2021.

The Patients' Experience of Severe Asthma Add-On Pharmacotherapies: A Qualitative Descriptive Study

Vanessa L Clark  1   2 , Peter G Gibson  1   3 , Vanessa M McDonald  1   2   3
Affiliations

The Patients' Experience of Severe Asthma Add-On Pharmacotherapies: A Qualitative Descriptive Study

Vanessa L Clark et al. J Asthma Allergy. .

Abstract

Purpose: Add-on therapies for severe asthma are continually emerging with proven efficacy in randomised controlled trials. To date, however, there are no qualitative studies exploring patients' experiences with these treatments. We aimed to understand the experience of patients who were treated with an add-on therapy for their severe asthma.

Patients and methods: A qualitative descriptive study was conducted, participants were recruited from the respiratory clinics and databases of a tertiary referral hospital. Participants with treatment-refractory severe asthma (n=20) prescribed an add-on therapy for >4 months (75% mepolizumab; 25% omalizumab, and 25% macrolide) were recruited. Qualitative semi-structured interviews were conducted, with interviews thematically analysed.

Results: Participants' mean (SD) age was 59.5 (15.3) years, and 50% were male. Participants reported 4.5 (2.3) exacerbations in the past year. Asthma Control Questionnaire score was 2.0 (1.4). The monoclonal add-on therapies had been prescribed for a median (IQR) of 12.5 (7.0, 24.0) months. Experience was captured in four emergent themes: "Life is just easier" provided an overall message that the add-on therapy made the participants' life easier in terms of increasing participation, levelling out symptoms, providing more energy and reducing healthcare use. "Prednisone: A necessary evil" was discussed, particularly in terms of dose and dependence and damaging side effects. The theme "worry and hope for the future" referenced treatment non-response or cessation of effect which was discussed by some participants. Finally, "holistic care" was centred on the sentiment that the participant's asthma management and overall health were not related to one aspect or medication alone.

Conclusion: Patients with severe asthma experience vast improvements in quality-of-life and life participation with add-on therapies, but there remains a significant burden related to oral corticosteroids and incomplete treatment responses. Addressing this residual burden is an important area for future research.

Keywords: asthma medications; monoclonal antibody therapies; patient experience; quality of life; severe asthma.

PubMed Disclaimer

Conflict of interest statement

Dr Vanessa Clark received a fellowship from the National Health and Medical Research Council, Centre of Research Excellence in Severe Asthma, and reports personal speaking fees from Astra Zeneca for work outside the submitted manuscript. Prof. Gibson reports personal fees from AstraZeneca, GlaxoSmithKline, Novartis, grants from AstraZeneca, GlaxoSmithKline, outside the submitted work. Prof. McDonald reports grants from Hunter Medical Research Institute, grants from National Health and Medical Research Council, grants from John Hunter Hospital Charitable Trust Research Grants, during the conduct of the study; grants and personal fees from GSK from Menarini for educational content, grants and personal fees from Astra Zeneca, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Themes (circles) and subthemes (boxes) for understanding the experience of add-on therapies in severe asthma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350–400. - PubMed
    1. McDonald VM, Gibson PG. Exacerbations of severe asthma. Clin Exp Allergy. 2012;42(5):670–677. doi:10.1111/j.1365-2222.2012.03981.x - DOI - PubMed
    1. McDonald V, Kennington E, Hyland M. Understanding the experience of people living with severe asthma. In: Chung K, Gibson P, editors. Severe Asthma (ERS Monograph). Sheffield: European Respirtory Society; 2019.
    1. McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology. 2019;24(1):37–47. doi:10.1111/resp.13389 - DOI - PubMed
    1. Stubbs M, Clark V, McDonald V. Living well with severe asthma. Breathe. 2019;15(2):e40–e49. doi:10.1183/20734735.0165-2019 - DOI - PMC - PubMed

LinkOut - more resources